These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18615002)

  • 1. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies.
    Yasuda SU; Zhang L; Huang SM
    Clin Pharmacol Ther; 2008 Sep; 84(3):417-23. PubMed ID: 18615002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
    Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
    J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in pharmacokinetics and pharmacodynamics.
    Gandhi M; Aweeka F; Greenblatt RM; Blaschke TF
    Annu Rev Pharmacol Toxicol; 2004; 44():499-523. PubMed ID: 14744256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental pharmacogenomics.
    Neville KA; Becker ML; Goldman JL; Kearns GL
    Paediatr Anaesth; 2011 Mar; 21(3):255-65. PubMed ID: 21320234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics and the future of toxicology testing.
    Agrawal YP; Rennert H
    Clin Lab Med; 2012 Sep; 32(3):509-23. PubMed ID: 22939305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.
    Phan VH; Tan C; Rittau A; Xu H; McLachlan AJ; Clarke SJ
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1395-410. PubMed ID: 21950349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing simple PK-PD studies in children.
    Thomson AH; Elliott HL
    Paediatr Anaesth; 2011 Mar; 21(3):190-6. PubMed ID: 21040154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of ethnic differences in drug disposition and response.
    Xie HG; Kim RB; Wood AJ; Stein CM
    Annu Rev Pharmacol Toxicol; 2001; 41():815-50. PubMed ID: 11264478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.
    Dostalek M; Akhlaghi F; Puzanovova M
    Clin Pharmacokinet; 2012 Aug; 51(8):481-99. PubMed ID: 22668340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.